# A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

> **NCT05562466** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QMF149
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT05562466
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-05-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05562466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05562466, "A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05562466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*